Literature DB >> 19250146

Aripiprazole in combination with other antipsychotic drugs may worsen psychosis.

J Adan-Manes1, P Garcia-Parajua.   

Abstract

Aripiprazole is a new generation antipsychotic drug with a partial agonist effect on dopamine D2 and D3 receptors. We report the case of a schizophrenic patient whose symptoms worsened after adding aripiprazole to another antipsychotic drug (amisulpiride). The physiopathology of this process seems to be mediated through the dopaminergic effect of aripiprazole in hypodopaminergic environments, caused by the administration of antipsychotic drugs such as amisulpiride. Besides this, the chronic administration of neuroleptic drugs may induce a hypersensitivity to dopamine agonists. In this context, we consider that the dopaminergic effect of aripiprazole may have induced a worsening of psychotic symptoms. We conclude that clinicians should be cautious when adding aripiprazole to patients under treatment with dopamine antagonists with a high affinity for D2 and D3 receptors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19250146     DOI: 10.1111/j.1365-2710.2008.00996.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  7 in total

1.  Psychotic exacerbation and emotional dampening in the daily life of patients with schizophrenia switched to aripiprazole therapy: a collection of standardized case reports.

Authors:  Johan Lataster; Inez Myin-Germeys; Marieke Wichers; Philippe A E G Delespaul; J van Os; Maarten Bak
Journal:  Ther Adv Psychopharmacol       Date:  2011-10

2.  Aripiprazole use combined with depot antipsychotic medication: two cases demonstrating its ability to reduce prolactin levels in an adolescent forensic hospital.

Authors:  Simon A Hill; Al Aditya Khan; Marion Wetherill
Journal:  Ther Adv Psychopharmacol       Date:  2011-06

Review 3.  A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder.

Authors:  Hiroyoshi Takeuchi; Gary Remington
Journal:  Psychopharmacology (Berl)       Date:  2013-06-05       Impact factor: 4.530

4.  A case series of serious and unexpected adverse drug reactions under treatment with cariprazine.

Authors:  Johannes Heck; Johanna Seifert; Dirk O Stichtenoth; Christoph Schroeder; Adrian Groh; Gregor R Szycik; Detlef Degner; Ivana Adamovic; Michael Schneider; Catherine Glocker; Eckart Rüther; Stefan Bleich; Renate Grohmann; Sermin Toto
Journal:  Clin Case Rep       Date:  2021-05-04

Review 5.  Recent Discussions on Dopamine Supersensitivity Psychosis: Eight Points to Consider When Diagnosing Treatment-Resistant Schizophrenia.

Authors:  Nobuhisa Kanahara; Hiroshi Kimura; Yasunori Oda; Fumiaki Ito; Masaomi Iyo
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708

6.  Aripiprazole monotherapy in an adolescent worsens psychosis.

Authors:  Mahima Panigrahi; Susanta Kumar Padhy; Rajesh Rathi
Journal:  Indian J Pharmacol       Date:  2013 Mar-Apr       Impact factor: 1.200

Review 7.  Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review.

Authors:  John Yin; Alasdair M Barr; Alfredo Ramos-Miguel; Ric M Procyshyn
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.